There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval. 2 "The burden of Crohn's disease on patients' ...

Hindenburg Research founder Nate Anderson, a foe of Carl Icahn and the Adani family, cites the stress of his job as he shuts down the firm.

Inflation data this week has come in below forecasts. Earnings season is off to a solid start. Is this the medicine the ...

The world's largest contract chip maker reported another record quarter as it continued to ride the AI wave while navigating the U.S.-China chip rivalry. The fatal shooting revealed deep resentment of ...

Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone and ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

The FDA approved Eli Lilly’s Omvoh in Crohn’s disease, the company announced Wednesday, handing the drug its second ...

BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...

Baltimore's school board joined districts across the country in suing drug makers over the skyrocketing costs of diabetes ...